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Abstract
Background: The European Medicines Agency (EMA) and national regulators share the responsibility to communicate to
healthcare providers postmarketing safety events but little is known about the consistency of this process. We aimed to
compare public availability of safety-related communications and drug withdrawals from the EMA and European Union
member countries for novel medicines.
Methods and Findings: We performed a cross-sectional analysis using public Dear Healthcare Professional Communications
(DHPCs) for all novel medicines authorized between 2001 and 2010 by the EMA and available for use in France, Netherlands,
Spain, and the United Kingdom. Between 2001 and 2010, the EMA approved 185 novel medicines. DHPCs could not be
ascertained for the EMA. Among the 4 national regulators, as of April 30, 2013, at least one safety DHPC or withdrawal
occurred for 53 (28.6%) medicines, totaling 90 DHPCs and 5 withdrawals. Among these 53 medicines, all 4 national agencies
issued at least one communication for 17 (32.1%), three of the four for 25 (47.2%), two of the four for 6 (11.3%), and one of
the four for 5 (9.4%). Five drugs were reported to be withdrawn, three by all four countries, one by three and one by two.
Among the 95 DHPCs and withdrawals, 20 (21.1%) were issued by all 4 national regulators, 37 (38.9%) by 3 of the 4, 22
(23.2%) by 2 of the 4, and 16 (16.8%) by one. Consistency of making publicly available all identified safety DHPC or
withdrawal across regulator pairs varied from 33% to 73% agreement.
Conclusions: Safety communications were not made publicly available by the EMA. Among the 4 European member
countries with national regulators that make DHPCs publicly available since at least 2001, there were substantial
inconsistencies in safety communications for novel medicines. The impact of those inconsistencies in terms of public health
remains to be determined.
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Introduction
The use of nearly all medical therapies carries both the potential
for patient benefit and risk, and this is especially true for
pharmaceutical products. The so called ‘‘life-cycle approach’’ to
drug evaluation, wherein benefits and risks are assessed not only
during the pre-market drug development period, but also
throughout the post-market ‘‘life’’ of the drug, is currently being
championed by leading regulators such as the U.S. Food and Drug
Administration (FDA) [1,2] and the European Medicines Agency
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109100
(EMA) [3]. But this emerging paradigm is contingent on an
effective post-marketing surveillance and communication system
for safety signals, so that physicians and patients are updated with
relevant contemporary information. Safety risks have been
communicated to healthcare providers and the public for decades
[4], however, despite their promise, they currently do not have a
principal role in a life cycle approach of drug evaluation. The
effectiveness and integrity of this communication system is chiefly
the responsibility of regulatory agencies.
In Europe, the EMA is responsible for approving the vast majority
of drugs but post-marketing safety surveillance is performed by both
the EMA and national regulatory agencies (http://www.ema.
europa.eu/ema/index.jsp?curl=pages/regulation/general/general_
content_000258.jsp&mid=WC0b01ac05800241de). When a safety
signal emerges, agencies are able to communicate publicly about
potentially unsafe drugs in several ways. Most commonly, a Direct
Healthcare Professional Communication (DHPC), so-called ‘‘Dear
doctor letter’’, is issued, the content of which should be agreed by the
manufacturer of the drug and by the agency prior to their
dissemination. The DHPC is then sent out to healthcare providers
in those countries where there is a need or a concern as per
agreement with the competent authority, i.e. most frequently the
national regulatory agency. Regulators also retain the authority to
revoke marketing authorization due to post-marketing safety
concerns, effectively withdrawing the drug from the market. As the
EMA and national agencies seem to share some regulatory
responsibilities, very little is known about how national agencies
disseminate DHPCs issued through the EMA or whether these
national agencies issue drug safety communications independently
and the consequent consistency of these communications across the
European Union (EU).
If drug safety communications are not consistently made
publicly available by local regulators after the EMA first acts to
call public attention to a safety concern, patients and healthcare
professionals are not being provided with complete and necessary
information to guide their decisions to use or prescribe a
medication. Similarly, if local regulators inconsistently make safety
communications public, conveying some but not others, it may
create public confusion given the close proximity and communi-
cation between EU member countries. Accordingly, our research
objective was to assess the consistency of DHPCs publicly
communicated among countries under the jurisdiction of the
EMA, with respect to both the availability of DHPCs and their
timing.
Methods
Novel Therapeutic Sample
For purposes of studying consistency in safety communications
across multiple European regulatory agencies, we studied a sample
of novel therapeutic agents approved by the EMA between
January 1, 2001 and December 31, 2010, by the Centralized
Authorization Procedure of the EMA, that had been developed for
prior work [5]. In brief, we identified all novel therapeutic agents
approved during this period, including small molecules and
biologics. We excluded reformulations, combinations therapies,
and nontherapeutic agents, such as radiographic dye.
European Regulatory Agencies Sample
To determine which European regulatory agencies should be
included for comparison, we first identified the ten countries of the
EU with the highest total drug sales in 2011 using IMS Health
data (Table 1; information provided at personal request by Loı¨c
Lebrun from IMS Health on April 2, 2013). We made such a
choice because we anticipated that those countries would be more
relevant for a regulatory study and in particular they would have
resources to implement an effective communicating infrastructure
to healthcare providers. Next, for each country, the national
regulatory agency for human medicines was identified through the
EMA’s website, via the ‘‘partners and networks’’ section, and we
determined whether each agency maintained its own website that
included a dedicated section for safety information, publicly
posting DHPCs as of 2001, the beginning of our novel therapeutic
sample period. We limited our study to agencies that maintain a
website containing a history of issued DHPCs, as this was the only
mean of systematically examining past communications. Of the 10
identified agencies, four had been providing DHPCs on-line since
2001: France, Netherlands, Spain, and United Kingdom.
Germany and Sweden only began providing DHPCs on-line after
2009, Belgium in 2011; Italy, Greece, and Poland do not currently
make DHPCs available via the internet.
EMA DHPC Search Strategy
Before searching each national agency website, we systemati-
cally searched the EMA website in order to determine whether a
DHPC had been issued for each of the novel medicines included in
our sample from January 2001 to April 2013, using both the brand
name and the name of the molecule. We initially searched within
the ‘‘Find Medicines’’ and ‘‘Human Medicines’’ sections of the
website, wherein the EMA maintains European Public Assessment
Reports, summarizing premarketing scientific discussion and post-
approval information. However, no systematic information on
DHPCs issued by the EMA was found, or elsewhere within other
sections of the website. The lack of full availability of these
communications was confirmed directly with EMA representatives
(personal communication with the Information Department,
March, 2013). Therefore, DHPCs were not made publicly
available by the EMA and could not be studied.
European Regulatory Agencies DHPC Search Strategy
For each national agency, we systematically performed a search
of their website in order to determine whether a DHPC, or Dear
Doctor Letter, had been made publicly available for each of the
novel medicines included in our sample between January 2001 to
April 2013, using both the brand(s) name(s) and the name of the
molecule. Each agency required a slightly modified search
strategy, tailored to the specifics of its website.
For the French National Agency (Agence nationale de se´curite´
du me´dicament et des produits de sante´, National Agency for the
Safety of Medicine and Healthcare Products, www.ansm.sante.fr),
we searched on the ‘‘information’’ section, then on the ‘‘safety
information’’ section, and then on the ‘‘letters to healthcare
professionals’’ providing a list of DHPCs and withdrawals issued
since December, 1998.
For the Dutch Agency (Medicines Evaluation Board, www.cbg-
meb.nl), we searched on the ‘‘human medicines’’ section, then on
the ‘‘pharmacovigilance’’ section, and then on the ‘‘Dear
Healthcare Professional Communications’’ section providing the
list of all DHPCs and withdrawals issued since November, 1998.
For the Spanish Agency (Spanish Agency for Medicines and
Health Products, www.aemps.gob.es), we searched on the
‘‘medicines for human use’’ section, then on the ‘‘safety warnings’’
section providing a list of DHPCs and withdrawals issued since
November, 1999.
Finally, for the United-Kingdom Agency (Medicines and
Healthcare Products Regulatory Agency, www.mhra.gov.uk), we
searched on the ‘‘safety information’’ section, then on the ‘‘safety
warnings, alerts and recalls’’ section, and then on the ‘‘safety
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warnings and messages for medicines’’ section providing a list of
DHPCs and withdrawals issued since April, 1999. From July,
2006, DHPCs issued by the MHRA are systematically gathered in
a subsection at the end of each month.
Identification of DHPCs and Withdrawals
For every DHPC or withdrawal identified during our search, we
determined whether the DHPC was communicating a safety
concern or whether the withdrawal was related to a safety issue.
For each, the following information was manually abstracted by
JDZ: full text of the DHPC or withdrawal (if given) and date(s) of
digital issuance (and not the date stated on the DHPC itself). If
necessary, translation of the DHPC was performed using Google
Translate (Google, Inc.; Mountain View, CA, USA). DHPCs
related to technical problems (dosage, route of administration,
quality defects), supply issues, or efficacy issues were not
categorized as safety communications and were subsequently
excluded. DHPCs communicating both safety and efficacy issues
were included.
Each time an inconsistency was identified regarding a DHPC or
withdrawal, a manual search was performed through the search
engine of the website and using Google to screen for a DHPC
inadvertently placed at other locations of the website and to
determine whether the product involved was effectively marketed
in the country that had not issued a DHPC or withdrawal.
Statistical Analysis
We used descriptive analysis to characterize each regulatory
agency sample, including the proportion of therapeutics for which
a safety DHPC or withdrawal was issued and the median number
of DHPCs issued per therapeutic.
We used percent agreement and kappa statistics to compare
whether national agencies issued a safety DHPC or withdrawal for
all novel therapeutics included in our sample, as well as for
products in which one or more safety events had been issued. If
one national regulator had issued a DHPC or withdrawal but the
product was not marketed in another national market that had
not, the regulators were considered to be ‘in agreement’.
The median test (Mood’s test) was used for analysis of delay
between the first and the last issue for any event (DHPC and
withdrawal) reported by two or more national regulatory agencies.
For therapeutics for which DHPCs/withdrawals were issued in
multiple countries, we calculated the time difference between
communications from the two (or more) regulatory agencies.
All tests were two sided, with the significance level set at 0.05.
Analyses were performed using JMP, Version 9 (SAS Institute
Inc.; Cary, NC, USA).
Results
From January 1, 2001 to December 31, 2010, 185 novel
therapeutic agents meeting the inclusion criteria were approved by
the EMA, among which 53 (28.6%) received at least one DHPC
safety communication or were withdrawn in at least one of the 4
countries from January 1, 2001 to April 30, 2013. Among these,
there was a total of 95 different safety communications, including 5
withdrawals. Overall, one safety communication was issued for 30
(56.6%) medicines, two for 11 (20.8%) medicines, three for 7
(13.2%), and four or more for 5 (9.4%).
Among the 53 novel medicines for which at least one safety
communication or withdrawal was issued, all 4 national regulatory
agencies issued at least one communication for 17 (32.1%), three
of the four for 25 (47.2%), two of the four for 6 (11.3%), and only
one of the four for 5 (9.4%) (Figure 1). Overall, the French
regulator issued at least one safety communication for 50 (28.3%)
of the medicines in our sample, the Dutch regulator 44 (23.9%),
the Spanish regulator 21 (11.4%), and the United-Kingdom
regulator 45 (24.5%).
Five drugs were withdrawn after approval, three by all four
countries (Thelin/Sitaxenten sodium; Raptiva/efalizumab; Acom-
plia/rimonabant), one withdrawal was reported by three countries
but was not marketed in the fourth (Tredaptive/laropiprant
suspended by Spain, UK and Netherlands, not marketed in
France), and one was reported by only two countries (Xigris/
drotrecogin alfa suspended by France and UK). For Sitaxenten
sodium, one DHPC was issued by one country (Spain) preceding
withdrawal approximately one month later. For efalizumab, two
DHPCs were issued preceding withdrawal, the first by France
related to peripheral neuropathy and a second related to
progressive multifocal leukoencephalopathy by three countries;
the medicine was withdrawn approximately three months later.
For rimonabant, two DHPCs were issued preceding withdrawal,
the first by three countries in July 2007 related to psychiatric
effects, the second approximately one year later by all four
countries for similar AEs; the medicine was withdrawn approx-
Table 1. Top ten European Union member countries, ranked by pharmaceutical expenditures, and public availability of Direct
Healthcare Professional Communications (including drug withdrawals).
European Pharmaceutical Market Public Availability of Direct Healthcare Professional Communications
Germany From September, 2009
France From December, 1998
Italy Unavailable
United-Kingdom From April, 1999
Spain From November, 1999
Poland Unavailable
Belgium From January, 2011
Netherlands From November, 1998
Greece Unavailable
Sweden From January, 2009
Source: IMS Health.
doi:10.1371/journal.pone.0109100.t001
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imately three months later. For laropiprant, one DHPC was issued
by two countries preceding its withdrawal approximately two
weeks later. Finally, for drotrecogin alfa, one DHPC was issued by
two countries (France, Netherlands) preceding its withdrawal by
two countries (France and UK). Detailed results are presented in
the appendix (see Appendix S1).
Consistency of issuing any safety DHPC or withdrawal for
medicines across national regulator pairs varied (Table 2,
Figure 1). The highest agreement was observed between the
national regulators of France and Netherlands (% agree-
ment = 95.7%; kappa = 0.89), whereas the lowest was observed
between France and Spain (% agreement = 83.1%; kappa = 0.47).
The kappa coefficients and corresponding 95% confidence
intervals for country-to-country comparison are detailed in
Table 2.
Among the 95 total safety communications and withdrawals
that were issued, 20 (21.1%) were issued by all 4 national
regulators, 37 (38.9%) by 3 of the 4, 22 (23.2%) by 2 of the 4, and
16 (16.8%) by only one (Figure 2). Consistency of issuing all
identified safety DHPC or withdrawal for medicines across
national regulator pairs also varied. The highest agreement was
observed between the national regulators of France and Nether-
lands (% agreement = 72.6%; kappa = 0.27), whereas the lowest
was observed between France and Spain (% agreement = 33.0%;
kappa =20.12).
Among the 79 safety DHPCs and withdrawals that were issued
by at least two regulators, the median time difference was 13.0
days (Interquartile Range [IQR]: 7–27). The greater the number
of regulators that issued DHPCs or withdrawals, the longer the
median time between the first and last communication; median
difference when two regulators issued safety communications was
9 days (IQR = 3.5-1), three regulators was 15 days (IQR = 7–28),
and four regulators was 21 days (IQR = 3–30) (p = 0.03).
The Netherlands and United Kingdom regulators each issued at
least one DHPC or withdrawal for 48 medicines and the median
time difference in these communications was 7 days (IQR = 2–13;
Table 3). In contrast, French and Spanish regulators each issued
at least one DHPC or withdrawal for 21 medicines and the
median time difference in these communications was 13.5 days
(IQR = 11–23). Spain consistently was the first to issue safety
communications when compared to the other individual agencies,
whereas France was consistently last, with time differing on
average from 9 to 14 days (Table 3, Figure 3).
Figure 1. Venn diagram demonstrating whether any safety
communication was reported by the four national regulatory
agencies for 53 novel medicines approved between 2001 and
2010.
doi:10.1371/journal.pone.0109100.g001
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Discussion
In our study of all novel therapeutic medicines approved by the
EMA from 2001 to 2010, we found that the EMA and European
national regulatory agencies do not comprehensively and consis-
tently publicly communicate post-marketing safety concerns. The
EMA does not currently display a publicly available list of safety-
related DHPCs issued since 2001 that had been transmitted to
national regulatory agencies. Among the top 10 highest prescrib-
ing EU countries, only 4, France, Netherlands, Spain and the
United-Kingdom, currently make DHPCs publicly available since
2001. Some countries like Germany, Belgium or Sweden have
only recently begun to display on their website information
regarding DHPCs. These findings suggest that patients and
physicians from the EU member countries are likely to face
difficulties and confusion when trying to obtain official and reliable
information about drug safety.
Among the 4 countries that have been making safety-related
DHPCs available to the public, we found many discrepancies in
the communications, both by therapeutic product and in the
specific communications. Many safety events were communicated
in few countries but not all, and even when all 4 countries issued a
DHPC for a given adverse event, we frequently observed
significant delays of public communications between regulators.
Of note is the fact that the French regulator was both the one that
issued the greater number of DHPCs and the slowest regulator on
average to publish them. Whether those two features are linked
and should be interpreted as rigorous and thorough, but
potentially slow, deserves further study.
There are several ways by which patients and physicians are
able to obtain updated information about drug safety, including
from the medical literature and directly from product manufac-
turers. However, information that is communicated directly by
regulators under the form of DHPCs is thought to represent the
mainstay of pharmacovigilance communication to physicians and
some authors have shown that DHPCs had been issued in
increasing numbers over the past decade [6]. The accessibility,
clarity and reliability of these DHPCs are paramount. If the
information they aim to disseminate is not effectively transmitted
to healthcare providers, drugs are more likely to be used or
prescribed without appropriate caution and likely without fully
informing patients of the true risks of the medicine, which has
potential implications for public health [7]. We found a relatively
high number of safety-related communications within the period
of interest, in line with previous reports [8] and in a way reassuring
in that it suggests that the system is functioning effectively to
communicate safety concerns across EU countries. However, the
quantity of pharmacovigilance statements provides only partial
reassurance given the observed inconsistencies among the four
examined regulators, particularly with respect to the kappa tests
for all 95 DHPCs or withdrawals identified as being publicly
Figure 2. Venn diagram demonstrating whether each of 95
safety communication was reported by the four national
regulatory agencies for 53 novel medicines approved between
2001 and 2010.
doi:10.1371/journal.pone.0109100.g002
Figure 3. Number and timing of 95 safety communications reported for 53 novel medicines approved between 2001 and 2010
among four national regulatory agencies.
doi:10.1371/journal.pone.0109100.g003
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available for the study period. Estimates indicate that agreement
between countries was only slight to fair, with scores below 0.41,
the accepted cut-off for moderate agreement [9].
There are several possible reasons for the discrepancy in public
safety communications among these four countries. First, national
regulators may be overwhelmed by administrative burden,
creating inconsistencies in safety communications. Second,
national regulators may be working under different safety policies,
such that some countries may believe that not all safety events are
required to be reported to healthcare providers under the form of
a DHPC. Such a choice could be justified by the fact that some
adverse events would not be of sufficient interest or by the concern
that issuing too many DHPCs could saturate clinicians to
appropriately process the communication.
At the very least, the EMA should begin to make publicly
available a list of safety-related DHPCs that had been transmitted
to national regulatory agencies. While the EMA is presently
engaging in a process of comprehensive transparency regarding
clinical trial data for medicines that have been or were considered
for approval [10], enhancing pharmacovigilance transparency is
equally important. It is the responsibility of the EMA to take over
the leadership for the improvement of the provision of advice to
the safe use of medicines. In this regard, it is worth noting that the
U.S. Food and Drug Administration has in recent years
committed to a significant endeavor to provide reliable, compre-
hensive and transparent safety information [1,2].
There are several limitations to our study. First, our search of
DHPCs was limited to the websites of the regulators being studied.
We cannot rule out the possibility of a regulator having prepared a
DHPC, or even communicating it with physicians or patients, but
not indexing it on the regulator’s website for public access.
However, because we used a systematic search strategy that
thoroughly scanned each regulator’s public communications and
because the purpose of our study was to examine the consistency
in public drug safety communications across European regulators,
any lack of online reporting can be interpreted as a failure of the
pharmacovigilance communication process. Second, we per-
formed manual searches to determine marketing status of all
drugs for which a DHPC had been issued by one national
regulator and not another. As none of the four national regulators
maintain a database of medications that have been approved for
use along with current marketing status, we may not have
accurately determined marketing status of all relevant medications.
Similarly, we performed manual searches of all national regulatory
agency websites for DHPCs and withdrawals because no
downloadable list of these safety communications was available.
It is possible that some DHPCs were not identified. In fact, several
adverse events communications were found through Google
searches within regulatory agency websites, but were not formally
issued as DHPCs. Similarly, the United-Kingdom uses a ‘‘Black
Triangle List’’ to bring attention to currently marketed drugs
under safety surveillance. But the list of drugs is long and these
concerns are not formally communicated to clinicians as DHPCs,
limiting their impact to inform physicians and patients. Never-
theless, for both searches, we used a systematic search strategy with
discussion and confirmation among multiple investigators. Finally,
we could not assess the actual impact of the observed inconsis-
tencies across national regulators in safety communications from a
public health perspective. Additional research is needed to
examine this issue.
In conclusion, we found that numerous safety-related DHPCs
were issued from 2001 to 2013 for all medicines approved by the
EMA between 2001 and 2010. However, safety communications
were not made publicly available by the EMA. Among the 4
European member countries with national regulatory agencies
that make DHPCs publicly available since 2001, there were
substantial inconsistencies in making safety communications public
for newly authorized medicines. Although the impact of these
differences could not be assessed, it raises questions about safety
policies and regulatory efficiency of the countries involved and
about the possible confusion it could provide among patients and
physicians.
Supporting Information
Appendix S1
(DOCX)
Acknowledgments
JD Zeitoun is grateful to Agne`s Lillo-Le Loue¨t for her gracious help on the
preliminary conception of this study and to Loı¨c Lebrun from IMS Health
for providing data about drug sales in the EU countries to be studied.
Author Contributions
Conceived and designed the experiments: JDZ JSR. Performed the
experiments: JDZ. Analyzed the data: JHL. Contributed reagents/
materials/analysis tools: JDZ JHL HB ND JSR. Wrote the paper: JDZ
JHL HB ND JSR. Provided supervision: HB JSR.
Table 3. Timing of making safety Direct Healthcare Professional Communications (DHPCs) or withdrawals publicly available
among medicines approved by the European Medicines Agency between 2001 and 2010 between national regulator pairs.
National Regulator Agency Pair
Common Safety
Communications, No.
National Regulatory
Agency First Issuing
Communication, No. (%)
Difference in Issuance of Safety
Communications Between National
Regulatory Agencies (Days)
Median InterQuartile Range
France UK 63 UK: 52 (82.5%) 12 7–25.5
France Netherlands 60 Netherlands: 38 (63.3%) 9 2.5–16
Netherlands UK 52 UK: 34 (65.4%) 5 1–12.5
France Spain 26 Spain: 14 (53.8%) 13.5 8–26
UK Spain 25 Spain: 14 (56%) 7.5 2.25–17.5
Netherlands Spain 25 Spain: 14 (56%) 7 2–13.5
doi:10.1371/journal.pone.0109100.t003
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